TUCSON, Ariz., Dec. 20, 2022 — Critical Path Institute (C-Path) today announced that the European Medicines Agency (EMA) has issued a letter of support for the Critical Path for Parkinson’s (CPP) Consortium’s Model-based Clinical Trial Simulation Platform to Optimize Design of Efficacy Evaluation Studies in Parkinson’s Disease (PD).Continue reading
Category Archives: AZBio News
C-Path’s Transplant Therapeutics Consortium Receives EMA Qualification Opinion for iBox Scoring System
The iBox Scoring System is available for use in kidney transplant clinical trials as a novel secondary endpoint prognostic for allograft loss.Continue reading
Arizona Legislative Leaders Discuss The Road Ahead
In 2023, Arizona will welcome a new governor and a new legislature. Watch the video for insights shared by Arizona’s incoming Senate President Pro Tem and incoming House Democratic Leader as they discuss the road ahead.
Recorded at the AZBio Trailblazers Luncheon on December 15, 2022. Continue reading
$10.8M initiative unites engineering and health researchers to improve cancer treatments
A University of Arizona project, with funding from the state’s New Economy Initiative, creates humanlike cancer models and growth environments to help improve prevention, diagnosis and treatment.Continue reading
Applications Open for Helios Scholars at TGen and TGen Bioscience Leadership Academy.
Do you want to experience what it’s really like to be a scientist?Continue reading
Arizona Center for Cancer Care Marks an Extraordinary Milestone Treating their 100th Patient with GammaTile Therapy for Brain Tumors
GammaTile® Therapy is FDA-cleared as a treatment for patients with newly diagnosed malignant intracranial neoplasms and patients with recurrent intracranial neoplasms, including brain metastases, glioblastomas, and meningiomas.Continue reading
UArizona Health Sciences Researchers Awarded $7.3M to Study Long COVID
The University of Arizona Health Sciences is one of five sites that will be tracking the burden, distribution and impact of post COVID-19 conditions.
Continue reading
HTG Molecular Diagnostics Announces the Next Event in its RNA Profiling in Drug Discovery KOL Webcast Series
TUCSON, Ariz., Dec. 09, 2022 (GLOBE NEWSWIRE) — HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling and advanced medicinal chemistry technology, today announced it will host its next HTG Therapeutics key opinion leader (KOL) webinar: “The Role of RNA Profiling in Drug Discovery and Analysis”, on Tuesday, December 13, 2022 at 11:00 am Eastern Standard Time.Continue reading
Aqualung Therapeutics, an Immunotherapeutics Biotech Company, Receives First $1.5M Toward Series A Preferred Capital Raise; Will Present at 2023 Annual Biotech Showcase
-JSR Lifesciences invested $1.5M toward the preferred series A capital raise, October 2022.
-The dosing of the P1A Healthy Human Volunteer Study with ALT-100 mAb is nearing completion, with no reported SAEs to date. Study to conclude by Q2 2023.Continue reading
PepSeq Provides Massive Platform for Antibody Analyses
Technology developed at TGen described in a new study.
PHOENIX, Ariz. — December 5, 2022 — With less than one microliter of blood plasma or serum, researchers can now use a customizable lab platform called PepSeq to observe how the tiny sample interacts with hundreds of thousands of protein building blocks.Continue reading